MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring Craf-Independent MEK Activation.
Lingtao Jin,Jaemoo Chun,Chaoyun Pan,Dan Li,Ruiting Lin,Gina N. Alesi,Xu Wang,Hee-Bum Kang,Lina Song,Dongsheng Wang,Guojing Zhang,Jun Fan,Titus J. Boggon,Lu Zhou,Jeanne Kowalski,Cheng-Kui Qu,Conor E. Steuer,Georgia Z. Chen,Nabil F. Saba,Lawrence H. Boise,Taofeek K. Owonikoko,Fadlo R. Khuri,Kelly R. Magliocca,Dong M. Shin,Sagar Lonial,Sumin Kang
DOI: https://doi.org/10.1016/j.ccell.2018.06.012
IF: 50.3
2018-01-01
Cancer Cell
Abstract:Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance limits their curative potential. Through a kinome RNAi screen, we identified microtubule-associated serine/threonine kinase 1 (MAST1) as a main driver of cisplatin resistance in human cancers. Mechanistically, cisplatin but no other DNA-damaging agents inhibit the MAPK pathway by dissociating cRaf from MEK1, while MAST1 replaces cRaf to reactivate the MAPK pathway in a cRaf-independent manner. We show clinical evidence that expression of MAST1, both initial and cisplatin-induced, contributes to platinum resistance and worse clinical outcome. Targeting MAST1 with lestaurtinib, a recently identified MAST1 inhibitor, restores cisplatin sensitivity, leading to the synergistic attenuation of cancer cell proliferation and tumor growth in human cancer cells and patient-derived xenograft models.